Qiagen N.V. (FRA:QIA)
40.49
-0.05 (-0.12%)
Last updated: Jun 23, 2025
Qiagen Revenue
Qiagen had revenue of $483.46M USD in the quarter ending March 31, 2025, with 5.37% growth. This brings the company's revenue in the last twelve months to $2.00B, up 3.31% year-over-year. In the year 2024, Qiagen had annual revenue of $1.98B with 0.66% growth.
Revenue (ttm)
$2.00B
Revenue Growth
+3.31%
P/S Ratio
4.80
Revenue / Employee
$371.18K
Employees
5,396
Market Cap
8.89B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.98B | 12.90M | 0.66% |
Dec 31, 2023 | 1.97B | -176.21M | -8.23% |
Dec 31, 2022 | 2.14B | -110.14M | -4.89% |
Dec 31, 2021 | 2.25B | 381.31M | 20.39% |
Dec 31, 2020 | 1.87B | 343.92M | 22.53% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.15B |
Siemens Aktiengesellschaft | 77.82B |
Deutsche Telekom AG | 120.25B |
Allianz SE | 109.03B |
Rheinmetall AG | 10.48B |
Siemens Energy AG | 37.44B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.84B |
Siemens Healthineers AG | 23.14B |
Qiagen News
- 1 day ago - QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board - Wallstreet:Online
- 1 day ago - QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board - Business Wire
- 8 days ago - Qiagen and Gencurix Enter Clinical Diagnostics Partnership - Market Watch
- 8 days ago - Qiagen and Gencurix partner for oncology tests - Seeking Alpha
- 8 days ago - QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership - Wallstreet:Online
- 8 days ago - QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership - Business Wire
- 11 days ago - Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket - Benzinga
- 12 days ago - QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) - Wallstreet:Online